Abiopharma

🔍 Jacques Kristine M (Director)

Company: Tenon Medical, Inc. (TNON)

Report Date: 2026-01-01

Detailed Transactions and Holdings:

• Acquired 10,146 shares of Common Stock (Direct)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,146.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 583 shares of Common Stock (Direct)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,729.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 10,146 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,147.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1, F1
• Sold 583 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 492.00 | transaction_form_type: 4 | Footnotes: F3, F2, F1, F1

Footnotes:

• F1: Represents conversion of 10,146 restricted stock units ("RSUs") granted to the reporting person on October 13, 2025 into 10,146 shares of common stock of the Issuer on January 1, 2026.
• F2: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
• F3: Represents conversion of 583 RSUs granted to the reporting person on May 8, 2024 into 583 shares of common stock of the Issuer on January 1, 2026.